SynCore Biotechnology Co (ROCO:4192) Total Equity: NT$245.63 Mil (As of Dec. 2025)


ROCO:4192 SynCore Biotechnology Co Ltd ROCO:4192
67 GF Score
Price NT$20.35
GF Value NT$47.88
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is SynCore Biotechnology Co Total Equity?

SynCore Biotechnology Co ROCO:4192 -2.86% 67 Total Equity is NT$245.63 Mil as of Dec. 2025. GuruFocus rates ROCO:4192 with a GF Score™ of 67/100 and a GF Value™ of NT$47.88 (Possible Value Trap). The stock has 1 warning sign investors should review.

SynCore Biotechnology Co's total equity for the quarter that ended in Dec. 2025 was NT$245.63 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

SynCore Biotechnology Co Total Equity Historical Data

* Premium members only.

The historical data trend for SynCore Biotechnology Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SynCore Biotechnology Co Total Equity Chart

SynCore Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 442.92 249.01 357.14 294.69 245.63

SynCore Biotechnology Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 294.69 279.85 265.98 257.97 245.63
ROCO:4192
67GF Score
SynCore Biotechnology Co Ltd ROCO:4192
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynCore Biotechnology Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

SynCore Biotechnology Co's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=255.702-10.074
=245.63

SynCore Biotechnology Co's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=255.702-10.074
=245.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$245.63 Mil mean?
SynCore Biotechnology Co (ROCO:4192) has a Total Equity of NT$245.63 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for SynCore Biotechnology Co and its competitors.
Is SynCore Biotechnology Co's Total Equity too high?
SynCore Biotechnology Co's current Total Equity is NT$245.63 Mil. Overall, SynCore Biotechnology Co has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SynCore Biotechnology Co's Total Equity compare to VRTX and REGN?
SynCore Biotechnology Co's Total Equity of NT$245.63 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for SynCore Biotechnology Co and its competitors. SynCore Biotechnology Co's current Total Equity is NT$245.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynCore Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, SynCore Biotechnology Co (ROCO:4192) is currently considered Possible Value Trap. The stock's GF Value™ is NT$47.88, compared to a current price of NT$20.35 — trading 57.5% below its estimated fair value. The current Total Equity is NT$245.63 Mil. SynCore Biotechnology Co's overall GF Score™ is 67/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For SynCore Biotechnology Co (ROCO:4192), the current Total Equity is NT$245.63 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SynCore Biotechnology Co (ROCO:4192) Overvalued in 2026?

Based on GuruFocus' analysis, SynCore Biotechnology Co stock appears to be undervalued. The current stock price of NT$20.35 is trading 57.5% below its estimated GF Value™ of NT$47.88. GuruFocus considers SynCore Biotechnology Co to be Possible Value Trap.

Key valuation signals for ROCO:4192:

  • Total Equity: NT$245.63 Mil
  • GF Value™: NT$47.88 vs. price of NT$20.35 (57.5% below fair value)
  • GF Score™: 67/100 with 1 warning sign

No single metric tells the full story. See the ROCO:4192 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SynCore Biotechnology Co Business Description

Address No. 84 Zhongshan Road, Zhongshan Village, Dongshan Township, Yilan, TWN, 269
SynCore Biotechnology Co Ltd is a biotechnology company. The pipeline products of the company include SB01 and 02, SB03, SB04, SB05, and Others. It is engaged in new drug development and sales, healthy food development and sales, medicine inspection, biotechnology services, and intellectual property. It operates in a single industry, the new drug development. The company generates the majority of its revenue from medical products and healthy food.
67GF Score

Get the complete analysis for ROCO:4192

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$20.35
Price
NT$47.88
GF Value